<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46963">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01982227</url>
  </required_header>
  <id_info>
    <org_study_id>1208138</org_study_id>
    <secondary_id>2012-004314-34</secondary_id>
    <nct_id>NCT01982227</nct_id>
  </id_info>
  <brief_title>Monocentric Prospective Pilot Study Evaluating the Value of Indocyanine Green (ICG, Indocyanine Green) During a Surgical Resection of Cancerous Lesions Peritoneal Colorectal Origin.</brief_title>
  <official_title>Monocentric Prospective Pilot Study Evaluating the Value of Indocyanine Green (ICG, Indocyanine Green) During a Surgical Resection of Cancerous Lesions Peritoneal Colorectal Origin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <authority>France: French Data Protection Authority</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Between 30% and 40% of patients with colorectal cancer develop metastatic disease
      intraperitoneally. The optimal treatment of this disease combines surgery and chemotherapy
      but requires resection of all lesions larger than 2mm.

      Indocyanine green has an affinity for tumor tissues and the interest of its use has been
      demonstrated for the detection of sentinel lymph node and some liver surgeries.

      The ability of indocyanine green to detect peritoneal carcinomatosis in humans has never
      been evaluated.

      This study aims to evaluate the diagnostic performance of fluorescence in the detection of
      malignant cells in peritoneal carcinomatosis of colorectal origin compared with pathological
      analysis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Sensitivity (true positive) of the fluorescence ex vivo compared to histological analysis s detected by fluorescence ex vivo</measure>
    <time_frame>At the end of the surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sensitivity (true positive) of the fluorescence ex vivo compared to histological analysis s detected by fluorescence ex vivo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specificity (true negative) of the in-vivo fluorescence compared to histological analysis s detected by fluorescence ex vivo peritoneal cancer index  (PCI) score with and without fluorescence</measure>
    <time_frame>At the end of the surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Specificity (true negative) of the in-vivo fluorescence compared to histological analysis s detected by fluorescence ex vivo PCI score with and without fluorescence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity (true negative) of the in-vivo fluorescence compared to histological analysis s detected by fluorescence ex vivo PCI score with and without fluorescence</measure>
    <time_frame>At de begining of the surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Specificity (true negative) of the in-vivo fluorescence compared to histological analysis s detected by fluorescence ex vivo PCI score with and without fluorescence</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>patients</arm_group_label>
    <description>Patients (Aged 18 to 70 inclusive) with progressive colorectal cancer in intra-abdominal surgery requiring resection +/- Chemotherapy Hyperthermic Intraperitoneal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indocyanine green</intervention_name>
    <description>intravenous injection (0.25mg/kg) of the indocyanine green 24h before the surgery.</description>
    <arm_group_label>patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with progressive colorectal cancer in intra-abdominal surgery requiring resection
        +/- Chemotherapy Hyperthermic Intraperitoneal
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with progressive colorectal cancer in intra-abdominal surgery requiring
             resection + / - Chemotherapy Hyperthermic Intraperitoneal

          -  Aged 18 to 70 inclusive

          -  Signature information form and consent by the patient

        Exclusion Criteria:

          -  Pregnant women, a urine pregnancy test or blood will be realized within 72 hours
             before surgery

          -  Contraindication to surgery

          -  Diagnosis not confirmed colorectal adenocarcinoma

          -  Persons major subject of legal protection or unable to consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabrielle BARABINO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabrielle BARABINO, MD</last_name>
    <phone>(0)477127717</phone>
    <phone_ext>+33</phone_ext>
    <email>gabrielle.barabino@chu-st-etienne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gabrielle BARABINO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 13, 2013</lastchanged_date>
  <firstreceived_date>November 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer metastatic</keyword>
  <keyword>indocyanine green</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
